查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1378981

临床前 CRO 市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Preclinical CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年，全球临床前CRO市场规模达到56亿美元。展望未来， IMARC Group预计到2028年该市场将达到87亿美元，2022-2028年复合年增长率（CAGR）为7.6%。研发（R＆D）活动支出不断增加、监管环境日益复杂、公司对核心能力的日益关注以及专业治疗的最新进展是推动市场的一些主要因素。

临床前合约研究组织（CRO）是指为生物技术、製药和医疗器材产业提供各种研发（R&D）服务的公司。它提供一系列服务，例如毒理学研究、药物动力学、製剂开发、监管支持和药效学研究。临床前 CRO 在药物发现、医疗器材测试、生物相容性、疾病建模、安全药理学和剂型选择方面有着广泛的应用。它有助于加快产品开发、增强法规遵循、利用专业知识、优化资源管理并提供可扩展的研究解决方案。

公司对核心能力的日益关注正在促进对临床前 CRO 的需求，以减轻专门的临床前任务并将更多资源投入其主要领域，例如后期临床试验或行销。此外，由于发展中国家製药业为应对独特的医疗保健挑战而迅速扩张，以及患者人数不断增长，对临床前 CRO 的需求不断增长，这也支撑了市场的成长。此外，个人化医疗、生物製剂和基因疗法等专业治疗的最新进展需要细緻的临床前测试，这也是另一个生长诱导因素。除此之外，由于药物开发的高失败率，临床前 CRO 的广泛采用为公司提供了风险平衡的方法，这也促进了市场的成长。除此之外，在成功的临床前研究中发挥关键作用的尖端技术的引入正在支持市场成长。

临床前 CRO 市场趋势/驱动因素：

研究与开发 (R&D) 活动支出不断成长

製药和生物製药行业的成长和活力与其对研发的承诺密不可分。对新颖疗法、更有效的治疗方法和突破性医疗解决方案的追求促使公司大力投资研发活动。随着疾病的变异和新的健康问题的出现​​，人们永远需要创新的药物和医疗设备。这种持续的创新驱动需要广泛的临床前研究，这些研究通常外包给 CRO，以利用他们的专业知识和设施。此外，抢先上市的竞争进一步加剧了研发工作。据此，外包临床前研究使公司能够快速进入药物开发的初始阶段，从而确保从实验室到患者的及时有效的路径。

监管环境日益复杂

全球製药格局正受到多方面、严格的监管框架的审查。这些监管机构制定了严格的标准，以确保各种产品的品质、安全性和功效。满足这些全面的要求需要专业知识、精确性和大量的文檔，这对许多公司来说往往是难以承受的。这就是临床前 CRO 的专业知识变得无价的地方。这些组织善于理解、驾驭并确保遵守此类复杂的法规。他们专注于临床前研究，确保他们随时了解最新的监管变化、采用最佳实践并维护符合全球标准的最先进的设施。此外，这有助于製药公司遵守监管要求，并最大限度地减少潜在的挫折，从而节省时间和资源。

药物开发过程的成本不断增加

药物开发是一项资本密集型工作，公司在药物的生命週期上投入大量资金。包括临床前研究在内的初始阶段尤其重要，因为它们为后续临床阶段奠定了基础。然而，在这些早期阶段建立和维护内部设施、技术和专业知识可能非常昂贵。透过外包给临床前 CRO，公司可以实现显着的成本效率。 CRO 提供可扩展的解决方案，让公司为其所需的特定服务付费。此外，由于其专注的性质，CRO 通常具有规模经济，将成本效益传递给客户。在财务审慎至关重要的世界中，外包临床前研究提供了平衡品质研究与经济考量的途径。

临床前CRO产业细分：

IMARC Group提供了全球临床前 CRO 市场报告各细分市场的主要趋势分析，以及 2023-2028 年全球、区域和国家层面的预测。我们的报告根据服务和最终用途对市场进行了分类。

按服务划分：

生物分析和 DMPK 研究

毒理学测试

其他的

毒理学测试主导市场

该报告根据服务提供了详细的市场细分和分析。这包括生物分析和 DMPK 研究、毒理学测试等。根据该报告，毒理学测试代表了最大的市场领域。

由于全球卫生当局製定了严格的监管要求，以确保识别对人类健康的潜在不利影响，毒理学测试正在主导市场。此外，随着药物变得越来越复杂，了解与生物系统潜在的毒性交互作用变得更加重要。现代药物，特别是基于新作用机製或生物製剂的药物，需要彻底的毒理学评估。此外，由于安全问题，许多候选药物在开发过程中失败。临床前阶段的毒理学测试有助于及早识别潜在的危险信号，透过防止不合适候选者的进展，为公司节省大量时间和财务资源。除此之外，体外毒理学、计算建模和高通量筛选等先进技术的出现，增强了毒理学研究的能力并提供更详细和快速的见解，正在推动市场成长。

按最终用途细分：

生物製药公司

政府和学术机构

医疗器材公司

生物製药公司主导市场

该报告根据最终用途提供了详细的市场细分和分析。这包括生物製药公司、政府和学术机构以及医疗器材公司。报告称，生物製药公司代表了最大的细分市场。

由于生物製剂（包括单株抗体、重组蛋白和基因疗法）的不断发展，生物製药公司正在主导市场，这些生物製剂需要彻底的临床前评估，通常需要 CRO 提供的专业知识。此外，生物製药实体正在大力投资研发，这转化为大量的临床前活动，其中许多活动被外包给 CRO 以提高效率和专业知识。除此之外，生物製剂的开发涉及使用活细胞的复杂生产过程。这种复杂性需要专门的临床前研究，包括对潜在杂质或污染物的评估。此外，生物製药因其潜在的免疫原性和独特的作用机製而受到严格的监管审查，这往往需要临床前 CRO 提供详细和专业的服务。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场占据明显主导地位，占据最大的临床前CRO市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是最大的细分市场。

由于许多领先的製药和生物技术公司的存在，北美在临床前 CRO 市场占据主导地位，这与临床前研究服务需求的增加直接相关。此外，区域公司在研发 (R&D) 投资方面始终处于领先地位。这种对创新的承诺推动了对临床前研究的巨大需求，从而推动了对专业 CRO 服务的需求。此外，北美领先的大学和研究机构提供最先进的基础设施并进行尖端研究。这个复杂的生态系统经常与 CRO 合作并补充其服务。除此之外，地方政府对药品安全提出严格的监管要求，也促进了对临床前合约研究机构满足严格要求并顺利通过复杂审批流程的需求。

竞争格局：

临床前 CRO 市场的顶尖公司正在扩大其产品组合，以提供端到端解决方案，涵盖从早期发现到临床前开发的所有内容，确保客户能够在同一屋檐下获得全套服务。此外，该公司正在投资体外毒理学、高通量筛选和计算建模等技术，以增强其临床前研究能力。此外，他们还透过建立新设施、升级现有设施或收购区域参与者来扩大全球业务。除此之外，一些市场参与者正在吸引顶尖人才并专注于持续培训，以确保他们的团队随时了解最新的科学进展和监管变化。此外，他们正在与製药公司建立长期合作，以简化药物开发流程、减少冗余并促进各方之间更深入的了解。

该报告对全球临床前CRO市场的竞争格局进行了全面分析。也提供了所有主要公司的详细资料。市场上的一些主要参与者包括：

查尔斯河实验室公司

科文斯公司（美国实验室控股公司）

欧陆科技

图示公司

MD Biosciences Inc.（传销医学实验室）

医疗空间

精锐国际公司

PPD公司

无锡药明康德

最近的发展：

2021年3月，Charles River Laboratories Inc.收购了Retrogenix，这是一家提供专业生物分析服务的早期CRO。

2020年10月，科文斯公司（美国实验室控股公司）宣布转型为去中心化的CRO。

2021 年 2 月，ICON Plc 宣布将收购 PRA Health Sciences，以巩固自身作为 CRO 的地位。

本报告回答的关键问题

  • 全球临床前CRO市场有多大
  • 2023-2028年全球临床前CRO市场的预期成长率是多少
  • 推动全球临床前CRO市场的关键因素是什么
  • COVID-19 对全球临床前 CRO 市场有何影响
  • 基于服务的全球临床前CRO市场的细分是怎样的
  • 根据最终用途，全球临床前 CRO 市场的细分如何
  • 全球临床前CRO市场的重点区域有哪些
  • 谁是全球临床前 CRO 市场的主要参与者/公司

本报告回答的关键问题

  • 全球临床前CRO市场有多大？
  • 2023-2028年全球临床前CRO市场的预期成长率是多少？
  • 推动全球临床前CRO市场的关键因素是什么？
  • COVID-19 对全球临床前 CRO 市场有何影响？
  • 基于该服务的全球临床前CRO市场的细分情况如何？
  • 根据最终用途，全球临床前 CRO 市场的细分如何？
  • 全球临床前CRO市场有哪些关键区域？
  • 全球临床前 CRO 市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球临床前 CRO 市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按服务分類的市场区隔

  • 生物分析和 DMPK 研究
    • 市场走向
    • 市场预测
  • 毒理学测试
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：依最终用途分類的市场区隔

  • 生物製药公司
    • 市场走向
    • 市场预测
  • 政府和学术机构
    • 市场走向
    • 市场预测
  • 医疗器材公司
    • 市场走向
    • 市场预测

第 8 章：按地区分類的市场区隔

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Charles River Laboratories Inc.
    • Covance Inc. (Laboratory Corporation of America Holdings)
    • Eurofins Scientific
    • ICON Plc
    • MD Biosciences Inc. (MLM Medical Labs)
    • Medpace
    • Parexel International Corporation
    • PPD Inc.
    • Wuxi AppTec
Product Code: SR112023A3715

Abstract

The global preclinical CRO market size reached US$ 5.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2028, exhibiting a growth rate (CAGR) of 7.6% during 2022-2028. The growing expenditure on research and development (R&D) activities, rising complexity of regulatory environment, increasing focus on core competencies among companies, and recent advancements in specialized treatments are some of the major factors propelling the market.

A preclinical contract research organization (CRO) refers to a company that provides various research and development (R&D) services to the biotechnology, pharmaceutical, and medical device industries. It offers a range of services, such as toxicology studies, pharmacokinetics, formulation development, regulatory support, and pharmacodynamics studies. Preclinical CRO finds extensive applications in drug discovery, medical device testing, biocompatibility, disease modeling, safety pharmacology, and dosage form selection. It aids in expediting product development, enhancing regulatory compliance, leveraging specialized expertise, optimizing resource management, and offering scalable research solutions.

The increasing focus on core competencies among companies is facilitating the demand for preclinical CROs to offload specialized preclinical tasks and dedicate more resources to their primary areas, such as late-phase clinical trials or marketing. Additionally, the rising demand for preclinical CRO due to the rapid expansion of the pharmaceutical sector in developing countries to address unique healthcare challenges and the growing patient population is supporting the market growth. Furthermore, the recent advancements in specialized treatments, such as personalized medicine, biologics, and gene therapies, which require nuanced preclinical testing, are acting as another growth-inducing factor. Apart from this, the widespread adoption of preclinical CROs to provide companies with a risk-balanced approach owing to the high failure rate of drug development is contributing to the market growth. Besides this, the introduction of cutting-edge technologies that play a pivotal role in successful preclinical studies is supporting the market growth.

Preclinical CRO Market Trends/Drivers:

The growing expenditure on research and development (R&D) activities

The growth and vitality of the pharmaceutical and biopharmaceutical sectors are inextricably linked to their commitment to R&D. The quest for novel therapeutics, more efficacious treatments, and groundbreaking medical solutions has propelled companies to invest heavily in R&D activities. As diseases mutate and new health concerns emerge, there's a perpetual need for innovative medications and medical devices. This continuous drive for innovation necessitates extensive preclinical studies, which are generally outsourced to CROs to harness their specialized expertise and facilities. Additionally, the competition to be first-to-market further intensifies R&D endeavours. In line with this, outsourcing preclinical research allows companies to swiftly navigate the initial stages of drug development, thus ensuring a timely and efficient path from the lab to the patient.

The rising complexity of regulatory environment

The global pharmaceutical landscape is under the scrutiny of multifaceted and rigorous regulatory frameworks. These regulatory bodies mandate stringent standards to ensure the quality, safety, and efficacy of various products. Meeting these comprehensive requirements demands expertise, precision, and extensive documentation, often overwhelming for many companies. This is where the specialized knowledge of preclinical CROs becomes invaluable. These organizations are adept at understanding, navigating, and ensuring compliance with such intricate regulations. Their dedicated focus on preclinical research ensures they remain updated with the latest regulatory changes, employ best practices, and maintain state-of-the-art facilities that adhere to global standards. Additionally, this helps pharmaceutical companies adhere to regulatory mandates and also minimizes potential setbacks, saving both time and resources.

The increasing cost of drug development process

Drug development is a capital-intensive endeavor, with companies investing heavily in the lifecycle of a drug. The initial stages, including preclinical studies, are especially critical as they set the foundation for subsequent clinical phases. However, establishing and maintaining in-house facilities, technologies, and expertise for these early stages can be expensive. By outsourcing to preclinical CROs, companies can achieve significant cost efficiencies. CROs offer scalable solutions, allowing companies to pay for the specific services they need. Additionally, CROs often have economies of scale due to their focused nature, passing on the cost benefits to their clients. In a world where financial prudence is paramount, outsourcing preclinical research provides an avenue to balance quality research with economic considerations.

Preclinical CRO Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global preclinical CRO market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on service and end use.

Breakup by Service:

Bioanalysis and DMPK Studies

Toxicology Testing

Others

Toxicology testing dominates the market

The report has provided a detailed breakup and analysis of the market based on the service. This includes bioanalysis and DMPK studies, toxicology testing, and others. According to the report, toxicology testing represented the largest market segment.

Toxicology testing is dominating the market due to the stringent regulatory requirements set by health authorities across the globe to ensure that potential adverse effects on human health are identified. Furthermore, as pharmaceuticals become more complex, understanding potential toxic interactions with biological systems becomes even more critical. Modern drugs, especially those based on novel mechanisms of action or biologics, require thorough toxicological evaluations. Additionally, many drug candidates fail during the development process due to safety concerns. Toxicology testing in the preclinical stage helps identify potential red flags early on, saving companies significant time and financial resources by preventing the progression of unsuitable candidates. Besides this, the advent of advanced technologies, such as in vitro toxicology, computational modeling, and high-throughput screening, which are enhancing the capabilities of toxicological studies and providing more detailed and rapid insights, is boosting the market growth.

Breakup by End Use:

Biopharmaceutical Companies

Government and Academic Institutes

Medical Device Companies

Biopharmaceutical companies dominate the market

The report has provided a detailed breakup and analysis of the market based on the end use. This includes biopharmaceutical companies, government and academic institutes, and medical device companies. According to the report, biopharmaceutical companies represented the largest market segment.

Biopharmaceutical companies are dominating the market due to the increasing development of biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, which require thorough preclinical evaluation, often necessitating specialized expertise that CROs provide. Furthermore, biopharmaceutical entities are investing heavily in R&D, which translates to a multitude of preclinical activities, many of which are outsourced to CROs for efficiency and expertise. Apart from this, the development of biologics involves intricate production processes using living cells. The complexity warrants specialized preclinical studies, including assessments of potential impurities or contaminants. Moreover, biopharmaceutical drugs are under intense regulatory scrutiny due to their potential immunogenicity and unique mechanisms of action, which often demand the detailed and specialized services of preclinical CROs.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market, accounting for the largest preclinical CRO market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market segment.

North America is dominating the preclinical CRO market owing to the presence of many leading pharmaceutical and biotech companies, which directly correlates with heightened demand for preclinical research services. Additionally, the regional firms consistently lead in terms of research and development (R&D) investments. This commitment to innovation drives a considerable need for preclinical studies, pushing the demand for specialized CRO services. Furthermore, leading universities and research institutions in North America provide state-of-the-art infrastructure and generate cutting-edge research. This sophisticated ecosystem often collaborates with and complements the services of CROs. Apart from this, the imposition of stringent regulatory requirements by regional governments regarding drug safety is facilitating the demand for preclinical CROs to meet rigorous requirements and navigate the intricate approval process.

Competitive Landscape:

The top companies in the preclinical CRO market are broadening their portfolio to provide end-to-end solutions, encompassing everything from early-stage discovery to preclinical development, which ensures clients can access a full suite of services under one roof. Additionally, companies are investing in technologies, such as in vitro toxicology, high-throughput screening, and computational modeling, to enhance their preclinical study capabilities. Furthermore, they are expanding their operations globally by setting up new facilities, upgrading existing ones, or acquiring regional players. Apart from this, several market players are attracting top talent and focusing on ongoing training to ensure their teams stay updated on the latest scientific advances and regulatory changes. Moreover, they are entering into long-term collaborations with pharmaceutical companies to streamline the drug development process, reduce redundancies, and foster deeper understanding between parties.

The report has provided a comprehensive analysis of the competitive landscape in the global preclinical CRO market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Charles River Laboratories Inc.

Covance Inc. (Laboratory Corporation of America Holdings)

Eurofins Scientific

ICON Plc

MD Biosciences Inc. (MLM Medical Labs)

Medpace

Parexel International Corporation

PPD Inc.

Wuxi AppTec

Recent Developments:

In March 2021, Charles River Laboratories Inc. acquired Retrogenix, an early-stage CRO providing specialized bioanalytical services.

In October 2020, Covance Inc. (Laboratory Corporation of America Holdings) announced it is transforming into a decentralized CRO.

In February 2021, ICON Plc announced that it is acquiring PRA Health Sciences to consolidate itself as a CRO.

Key Questions Answered in This Report

  • 1. How big is the global preclinical CRO market?
  • 2. What is the expected growth rate of the global preclinical CRO market during 2023-2028?
  • 3. What are the key factors driving the global preclinical CRO market?
  • 4. What has been the impact of COVID-19 on the global preclinical CRO market?
  • 5. What is the breakup of the global preclinical CRO market based on the service?
  • 6. What is the breakup of the global preclinical CRO market based on the end use?
  • 7. What are the key regions in the global preclinical CRO market?
  • 8. Who are the key players/companies in the global preclinical CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Preclinical CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Service

  • 6.1 Bioanalysis and DMPK Studies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Toxicology Testing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End Use

  • 7.1 Biopharmaceutical Companies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Government and Academic Institutes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Medical Device Companies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Charles River Laboratories Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Covance Inc. (Laboratory Corporation of America Holdings)
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 SWOT Analysis
    • 13.3.3 Eurofins Scientific
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 ICON Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 MD Biosciences Inc. (MLM Medical Labs)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Medpace
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Parexel International Corporation
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 SWOT Analysis
    • 13.3.8 PPD Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Wuxi AppTec
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials

List of Figures

  • Figure 1: Global: Preclinical CRO Market: Major Drivers and Challenges
  • Figure 2: Global: Preclinical CRO Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Preclinical CRO Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Preclinical CRO Market: Breakup by Service (in %), 2022
  • Figure 5: Global: Preclinical CRO Market: Breakup by End Use (in %), 2022
  • Figure 6: Global: Preclinical CRO Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Preclinical CRO (Bioanalysis and DMPK Studies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: Preclinical CRO (Bioanalysis and DMPK Studies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: Preclinical CRO (Toxicology Testing) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Preclinical CRO (Toxicology Testing) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Preclinical CRO (Other Services) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Preclinical CRO (Other Services) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Preclinical CRO (Biopharmaceutical Companies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Preclinical CRO (Biopharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Preclinical CRO (Government and Academic Institutes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Preclinical CRO (Government and Academic Institutes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Preclinical CRO (Medical Device Companies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Preclinical CRO (Medical Device Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: North America: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: North America: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: United States: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: United States: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Canada: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Canada: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Asia-Pacific: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Asia-Pacific: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: China: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: China: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Japan: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Japan: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: India: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: India: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: South Korea: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: South Korea: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Australia: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Australia: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Indonesia: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Indonesia: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Others: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Others: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Europe: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Europe: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Germany: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Germany: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: France: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: France: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: United Kingdom: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: United Kingdom: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Italy: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Italy: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Spain: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Spain: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Russia: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Russia: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Others: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Others: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Latin America: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Latin America: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Brazil: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Brazil: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Mexico: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Mexico: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Others: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Others: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Middle East and Africa: Preclinical CRO Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Middle East and Africa: Preclinical CRO Market: Breakup by Country (in %), 2022
  • Figure 67: Middle East and Africa: Preclinical CRO Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Global: Preclinical CRO Industry: SWOT Analysis
  • Figure 69: Global: Preclinical CRO Industry: Value Chain Analysis
  • Figure 70: Global: Preclinical CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Preclinical CRO Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Preclinical CRO Market Forecast: Breakup by Service (in Million US$), 2023-2028
  • Table 3: Global: Preclinical CRO Market Forecast: Breakup by End Use (in Million US$), 2023-2028
  • Table 4: Global: Preclinical CRO Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: Preclinical CRO Market: Competitive Structure
  • Table 6: Global: Preclinical CRO Market: Key Players